MIA
SNDX icon

MeadowBrook Investment Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

MeadowBrook Investment Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,500
Closed -$18.4K – 291
2025
Q1 		$18.4K Hold
1,500
– – 0.02% 227
2024
Q4 		$19.8K Hold
1,500
– – 0.02% 226
2024
Q3 		$28.9K Sell
1,500
-200
-12% -$4.13K 0.03% 200
2024
Q2 		$34.9K Hold
1,700
– – 0.03% 186
2024
Q1 		$40.5K Hold
1,700
– – 0.04% 182
2023
Q4 		$36.7K Buy
+1,700
New +$26.1K 0.04% 183

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

MeadowBrook Investment Advisors's SNDX Position: Q2 2025 in Review

MeadowBrook Investment Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q2 2025, closing a stake of 1,500 shares — an estimated $18.4K sold.

MeadowBrook Investment Advisors first reported a position in SNDX in Q4 2023 and held it in 6 quarters. The position peaked at $40.5K in Q1 2024. 216 funds tracked by Wall St. Rank hold SNDX as of Q2 2025.

  • MeadowBrook Investment Advisors reported no remaining Syndax Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • MeadowBrook Investment Advisors sold 1,500 Syndax Pharmaceuticals shares in Q2 2025, an estimated $18.4K.
  • MeadowBrook Investment Advisors first reported a position in Syndax Pharmaceuticals in Q4 2023 and held it in 6 quarters.
  • MeadowBrook Investment Advisors's Syndax Pharmaceuticals position peaked at $40.5K in Q1 2024.
  • 216 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2025.

Based on MeadowBrook Investment Advisors's 13F filing for Q2 2025, filed 4 Aug 2025.